Gilead Sciences Inc.

News & Events

Press Releases

In The Media

1. Gilead Sciences to Present at Upcoming Investor Conferences

   Business Wire NOV 4, 2025 4:05 PM EST
   Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the ...
   Read Article

2. Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

   Business Wire NOV 3, 2025 9:10 AM EST
   – Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refracto...
   Read Article

3. Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

   Business Wire OCT 31, 2025 8:00 AM EDT
   Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Pri...
   Read Article

4. Gilead Sciences Announces Third Quarter 2025 Financial Results

   Business Wire OCT 30, 2025 4:02 PM EDT
   Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sale...
   Read Article

5. Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

   Business Wire OCT 23, 2025 8:00 AM EDT
   - Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi ...
   Read Article

6. LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

   Canada Newswire OCT 21, 2025 7:00 AM EDT
   LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY ...
   Read Article

7. Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

   Business Wire OCT 19, 2025 8:30 AM EDT
   – Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo...
   Read Article

8. Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

   Business Wire OCT 19, 2025 2:30 AM EDT
   – Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The ...
   Read Article

9. Gilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention

   Business Wire OCT 15, 2025 3:30 AM EDT
   – New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophyla...
   Read Article

10. Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

    Business Wire OCT 13, 2025 8:30 AM EDT
    – Late-breaking Phase 3 ASCENT-03 Study Results Highlight Potential for Trodelvy ®...
    Read Article